Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review.
Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.
['Yan|Zheng|Z|0000-0001-9324-2161', 'Yao|Zhi-Hua|ZH|', 'Yao|Shu-Na|SN|', 'Xia|Qing-Xin|QX|', 'Wang|Hai-Ying|HY|', 'Chu|Jun-Feng|JF|', 'Song|Ming|M|', 'Zhao|Shuang|S|', 'Liu|Yan-Yan|YY|0000-0002-3887-0840']
nivolumab radiotherapy primary mediastinal large B-cell lymphoma immunotherapy